Results 191 to 200 of about 3,091,688 (344)
Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann +15 morewiley +1 more sourceGenome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease
Nature Genetics, 2013 D. Harold, R. Abraham, P. Hollingworth, R. Sims, A. Gerrish, M. Hamshere, J. S. Pahwa, V. Moskvina, Kimberley Dowzell, Amy J. Williams, N. Jones, C. Thomas, A. Stretton, A. Morgan, S. Lovestone, J. Powell, P. Proitsi, Michelle K. Lupton, C. Brayne, D. Rubinsztein, M. Gill, B. Lawlor, A. Lynch, K. Morgan, K. Brown, P. Passmore, D. Craig, B. McGuinness, S. Todd, C. Holmes, D. Mann, A. Smith, S. Love, P. Kehoe, J. Hardy, S. Mead, N. Fox, M. Rossor, J. Collinge, W. Maier, F. Jessen, B. Schürmann, R. Heun, H. Bussche, I. Heuser, J. Kornhuber, J. Wiltfang, M. Dichgans, L. Frölich, H. Hampel, M. Hüll, D. Rujescu, A. Goate, J. Kauwe, Carlos Cruchaga, P. Nowotny, J. Morris, K. Mayo, K. Sleegers, K. Bettens, S. Engelborghs, P. Deyn, C. Broeckhoven, G. Livingston, N. Bass, H. Gurling, A. McQuillin, R. Gwilliam, P. Deloukas, A. Al-Chalabi, C. Shaw, M. Tsolaki, A. Singleton, R. Guerreiro, Thomas W. Mühleisen, M. Nöthen, S. Moebus, K. Jöckel, N. Klopp, H. Wichmann, M. Carrasquillo, V. Pankratz, S. Younkin, P. Holmans, M. O’Donovan, M. Owen, Julie Williams +86 moresemanticscholar +1 more sourceClass IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio +13 morewiley +1 more sourceIn vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations
Molecular Oncology, EarlyView.Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow +10 morewiley +1 more sourceAdditional file 5: of Unraveling the Genetic Elements Involved in Shoot and Root Growth Regulation by Jasmonate in Rice Using a Genome-Wide Association Study
, 2019 Huong To, Hieu Trung Nguyen, Nguyet Dang, Ngan Nguyen, Thai Q. Bui, Jérémy Lavarenne, Nhung Thi Phuong Phung, Pascal Gantet, Michel Lebrun, Stéphane Bellafiore, Antony Champion +10 moreopenalex +1 more source
